N
Nicholas E. Ingraham
Researcher at University of Minnesota
Publications - 52
Citations - 1134
Nicholas E. Ingraham is an academic researcher from University of Minnesota. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 10, co-authored 33 publications receiving 518 citations.
Papers
More filters
Journal ArticleDOI
Immunomodulation in COVID-19.
Nicholas E. Ingraham,Sahar Lotfi-Emran,Beth K Thielen,Kristina Techar,Rachel Morris,Shernan G. Holtan,R. Adams Dudley,Christopher J. Tignanelli +7 more
TL;DR: A systematic review and meta-analysis of randomized clinical trials found that PD-1 inhibitor-related pneumonitis in advanced cancer patients: Radiographic patterns and clinical course may be related to duration of infection.
Journal ArticleDOI
Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis
Carolyn T. Bramante,Nicholas E. Ingraham,Thomas A. Murray,Schelomo Marmor,Shane Hovertsen,Jessica Gronski,Chace McNeil,Ruoying Feng,Gabriel Guzman,Nermine Abdelwahab,Samantha King,Leonardo Tamariz,Thomas Meehan,Kathryn M. Pendleton,Bradley Benson,Deneen Vojta,Christopher J. Tignanelli +16 more
TL;DR: Metformin was significantly associated with reduced mortality in women with obesity or type 2 diabetes who were admitted to hospital for COVID-19, and metformin could be widely distributed for prevention of CO VID-19 mortality, because it is safe and inexpensive.
Journal ArticleDOI
Understanding the renin-angiotensin-aldosterone-SARS-CoV axis: a comprehensive review.
Nicholas E. Ingraham,Abdo G. Barakat,Ronald Reilkoff,Tamara Bezdicek,Timothy W. Schacker,Jeffrey G. Chipman,Christopher J. Tignanelli,Michael A. Puskarich,Michael A. Puskarich +8 more
TL;DR: A preponderance of evidence is proposed that supports clinical equipoise regarding the efficacy of RAAS-based interventions, and the imminent need for a multisite randomised controlled clinical trial to evaluate the inhibition of the RAAS–SCoV axis on acute lung injury in COVID-19 is proposed.
Journal ArticleDOI
Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19.
Carolyn T. Bramante,Jared D. Huling,Christopher J. Tignanelli,John B. Buse,David Liebovitz,Jacinda M Nicklas,Ken Cohen,Michael A. Puskarich,Hrishikesh Belani,Jennifer Proper,Lianne Siegel,Nichole R. Klatt,David J. Odde,Darlette Luke,Blake Anderson,Amy B. Karger,Nicholas E. Ingraham,K. Hartman,V Chandrashekar Rao,A. Hagen,Barkha Patel,S. Fenno,Nandini Avula,N. V. Reddy,S. M. Erickson,S. Lindberg,Regina Fricton,Samuel S. O. Lee,Adnin Zaman,Hanna G. Saveraid,Walker J. Tordsen,Matthew F Pullen,Michelle H. Biros,Nancy E. Sherwood,Jennifer Leigh Thompson,David R. Boulware,Thomas A. Murray +36 more
TL;DR: None of the three medications that were evaluated prevented the occurrence of hypoxemia, an emergency department visit, hospitalization, or death associated with Covid-19.
Posted ContentDOI
Observational Study of Metformin and Risk of Mortality in Patients Hospitalized with Covid-19
Carolyn T. Bramante,Nicholas E. Ingraham,Thomas A. Murray,Schelomo Marmor,Shane Hoversten,Jessica Gronski,Chace McNeil,Ruoying Feng,Gabriel Guzman,Nermine Abdelwahab,Samantha King,Thomas Meehan,Bradley Benson,Kathryn M. Pendleton,Deneen Vojta,Christopher J. Tignanelli +15 more
TL;DR: Metformin was significantly associated with reduced mortality in women with obesity or T2DM in observational analyses of claims data from individuals hospitalized with Covid-19, suggesting that metformin conveys protection in Covid19 through TNF-alpha effects.